Comparative Pharmacology
Head-to-head clinical analysis: DOLENE versus DOLISHALE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOLENE versus DOLISHALE.
DOLENE vs DOLISHALE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Opioid agonist, primarily mu-opioid receptor activation, leading to analgesic and euphoric effects.
DOLISHALE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, enhancing serotonin neurotransmission.
50 mg orally every 4-6 hours as needed for pain; maximum 400 mg per day.
Adults: 200 mg orally twice daily or 400 mg orally once daily. Administer with food.
None Documented
None Documented
2.5-3.5 hours; prolonged in hepatic impairment (up to 6-8 hours) and in neonates.
Terminal elimination half-life: 12 hours (range 10-14) in adults; prolonged in renal impairment (up to 24 hours with CrCl <30 mL/min)
Renal: 70-80% as conjugated metabolites (mostly glucuronides), 5-10% as unchanged drug; Fecal: 5-10%; Biliary: minor.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Opioid Analgesic
Opioid Analgesic